FDA Grants AP Status for Acetazolamide Sodium ANDA200880
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Acetazolamide Sodium submitted by Mylan ASI.
Therapeutic Area
Therapeutic area intelligence for Carbonic Anhydrase Inhibitor with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Heritage Pharma has received an approval update for a supplement application for Acetazolamide.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.